Your browser is outdated! Try to open this webpage in another browser.
Aller au contenu



ORPEA is a European leader in dependency care, operating nursing homes, post-acute and rehabilitation clinics, psychiatric care clinics and home care services (serviced residences, day care, home-based services and day-time and night-time hospital services).

As at December 31, 2022

The group operates in 22 countries and has three business areas: care for older adults (nursing homes, assisted living facilities, home-based care and services), post-acute and rehabilitation care, and mental health care (specialist clinics). It has more than 72,000 employees and each year cares for more than 255,000 patients and residents.

Stake in ORPEA
5 %
Investment date

Peugeot Invest's investment

Peugeot Invest invested in ORPEA in July 2011, buying some of its shares from the founder and others on the market. Peugeot Invest increased its interest in ORPEA when the latter carried out a €203 million capital increase in 2011.

On 26 July 2018, after seven years as a shareholder, Peugeot Invest sold 550,000 ORPEA shares, representing around 0.85% of the company’s equity, for €63.8 million.

At 31 December 2022, the Peugeot Invest group (via wholly owned subsidiary Peugeot Invest Assets) held 5.0% of the group. The value of the shareholding, for the purposes of Net Asset Value and the consolidated financial statements, is based on the share price at 31 December 2022.

At 31 December 2022, Peugeot Invest Assets, represented by Bertrand Finet, had a seat on ORPEA’s Board of Directors, was a member of its CSR and Innovation Committee and chaired its Appointments and Remuneration Committee.

In 2022

Revenue totalled €4,681 million in 2022, an increase of 8.9% relative to 2021, including organic growth of 5.5%. Revenue in France rose by 2.1%, including organic growth of 1.9%, and remained significantly hampered by the crisis affecting the Group’s nursing homes. Growth was strong in the group’s other geographical markets. It mainly consisted of organic growth, driven by a recovery related to the gradual emergence from the Covid-19 crisis, the build-up of newly opened facilities and price increases in the second half of 2022 in countries such as Germany and Belgium.

The group is due to report 2022 results in the second quarter of 2023. ORPEA’s performance was badly affected by the reputational crisis that began in 2021, leading to an overhaul of its governance including the appointment of a new Board of Directors and a new management team.

On 25 October 2022, the group began non-contentious conciliation proceedings, seeking discussions with its creditors about restructuring its debt, obtaining new financial resources and adjusting its covenants. The group also commenced proceedings against unnamed persons and against its former CEO. On 15 November 2022, management presented a “refoundation plan” and continued discussions with its creditors.

In early 2023, ORPEA reached an agreement in principle with its main banking partners and began an accelerated safeguard procedure to allow it to implement its restructuring plan. As the company noted, the capital increases being considered as part of its restructuring plan would lead to large-scale dilution for existing shareholders (see section 4.3 of its Universal Registration Document).

Key figures

Number of patients
3.9 bn

Shareholding structure

14.5 %
5 %
Peugeot Invest
80.5 %